Spots Global Cancer Trial Database for Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer
Official Title: Managed Access Program (MAP) Cohort Treatment Plan CBYL719C2001M to Provide Access to Alpelisib (BYL719) for Patients With HR-positive, HER2-negative Advanced Breast Cancer With Mutated Phosphoinositide 3-kinase Who Progressed on or After AI Treatment
Study ID: NCT04473040
Conditions
Interventions
Study Description
Brief Summary: The purpose of this Cohort Treatment Plan is to allow access to alpelisib for patients diagnosed with HR-positive, HER2-negative advanced breast cancer with mutated phosphoinositide 3-kinase who progressed on or after AI treatment. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
